113 results about "Thrombin" patented technology

The invention relates to the technical field of tumor biomedical engineering and organ chips, in particular to a vascularized gastric cancer organ chip and a preparation method thereof.The chip is composed of an integrated micro-fluidic main body, an annular micro-column array and an optical sealing film, and a central culture cavity is divided into a tumor area and a blood vessel area by micro-columns; the preparation method comprises the following steps: injecting a fibrous protein solution containing human umbilical vein endothelial cells and cancer-related fibroblasts into a vascular region, and adding thrombin for in-situ gelation to form a pre-vascularized network; the method comprises the following steps: mixing a patient-derived gastric cancer organ with a methacrylic acid esterified gelatin pre-polymerized solution, injecting the mixture into a tumor area, and carrying out photo-crosslinking immobilization; culturing for 7-14 days under the dynamic perfusion condition of a mixed culture medium to obtain a three-dimensional gastric cancer organ model containing a capillary network; the method is expected to be used for rapid, low-cost and high-throughput screening of chemotherapy or anti-angiogenesis drugs and accurate prediction of individual curative effects of patients.

The invention discloses a preparation method and application of autologous fibrin glue, and belongs to the field of biomedical materials. The preparation method comprises the following five steps: collecting autologous venous blood, adding a sodium citrate anticoagulant with the volume ratio of 1: (8-12), and storing at 4-6 DEG C for not more than 2 hours; performing step-by-step centrifugation at the speed of 1500 to 2000 r / min and the speed of 3500 to 4000 r / min to obtain a fibrinogen concentrate; the thrombin-calcium chloride activation solution A and the tranexamic acid activation solution B are mixed according to the ratio of 1: (2-3) to form a composite activation system; mixing the two components according to a mass ratio of 1: (0.8-1.2), and reacting at 25-37 DEG C for 3-5 minutes to form colloid; and pre-freezing at-40 to-60 DEG C, performing vacuum freeze-drying, and storing at 4-8 DEG C. During application, the colloid can be coated on an operation wound surface after being redissolved, or mixed with a growth factor to prepare a dressing for covering a chronic wound surface. The colloid is high in purity, stable in coagulation time, long in storage period, suitable for scenes such as surgical hemostasis and the like, and high in clinical value.

The invention relates to the technical field of biomedical materials, and discloses an antibacterial hemostatic material and a preparation method thereof, the antibacterial hemostatic material comprises the following components by weight: 2-3 parts of amino acid terminated polyurethane, 1-3 parts of thiolated chitosan, 3-5 parts of sodium alginate, and 2-4 parts of a polyvinyl alcohol solution. Through the synergistic effect of amino acid terminated polyurethane-sulfhydrylated chitosan-sodium alginate, a dual hemostatic mechanism of physical adsorption-chemical coagulation promotion is constructed: sodium alginate as a natural polysaccharide has strong hydrophilicity and cation adsorption capacity, can quickly absorb moisture in wound blood, concentrate platelets and coagulation factors, and has a good hemostatic effect; thrombin activation is accelerated, and the blood coagulation time is shortened; the antibacterial hemostatic material disclosed by the invention has relatively good antibacterial and hemostatic effects.

The invention provides a wound hemostasis device for the emergency department, and relates to the technical field of wound hemostasis. The wound hemostasis device for the emergency department comprises an inflatable hemostasis air bag, and a constant-temperature film bag is fixedly connected to the lower surface of the inflatable hemostasis air bag. During working, a second infusion pump is started and pumps water in a constant-temperature water storage tank through a second infusion pipeline, the water enters a constant-temperature film bag through a fourth infusion pipeline, the temperature of a wound is guaranteed, meanwhile, a first infusion pump is started, a first water valve on a first infusion pipeline is opened, and a second water valve on a second infusion pipeline is opened. Water in the constant-temperature film bag is pumped through the first liquid pumping pipeline, and finally the water enters the constant-temperature water storage tank, so that the water in the constant-temperature film bag is always in a constant-temperature state, the temperature is ensured to be close to the optimum point of thrombin reaction, platelet aggregation and fibrin formation can be accelerated, and the method is safe and efficient, can minimize tissue damage, and is suitable for clinical application. And the hemostasis speed is accelerated.

The invention belongs to the field of biomedical materials, and particularly relates to a coagulation-promoting embolism microsphere and a preparation method thereof. The sericin-based embolism microspheres are creatively prepared, and the sericin membrane layer on the surface of the microspheres can prevent the risk that a catheter is solidified during an operation due to thrombin burst release during the operation. On the other hand, sericin in the microspheres has excellent water absorption swelling property and lubricity, and is beneficial to embolism and prevention of reflux; moreover, sericin molecules contain a large amount of hydroxyl and carboxyl, so that the chelation of blood coagulation factor calcium ions is greatly improved. In addition, thrombin factors are loaded into the microspheres, calcium ions are chelated on the surfaces of the microspheres, the microspheres are endowed with rapid embolism capacity through the superimposed effect, blood flow blocking of target blood vessels can be effectively accelerated, and reflux is prevented. The prepared procoagulant embolism microspheres are suitable for being applied to treatment of vascular-rich tumors of the brain and can effectively prevent mistaken closure of many complex functional blood vessels of the brain due to reflux.

Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg / ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water.

The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

The invention discloses a nucleic acid aptamer with enhanced affinity after cyclic hybridization as well as a screening method and application thereof, relates to the technical field of nucleic acid aptamer screening, and successfully develops a CH-SELEX method by taking human alpha-thrombin as a research object on the basis of compatibility with MB-SELEX under the condition of introducing cyclic hybridization. Through multiple rounds of positive screening under the condition of introducing cyclic hybridization and negative screening under the condition of adding His-small peptide modified magnetic beads and human serum, the nucleic acid aptamer which can specifically recognize human alpha-thrombin and has obviously improved affinity after cyclic hybridization is screened; and the affinity of the nucleic acid aptamer can be regulated and controlled by increasing the length of the hybrid complementary chain, so that reference is provided for diagnosis and treatment of diseases related to human alpha-thrombin and development of sensors, concept verification and methodological reference is provided for regulation and control of other important biological processes, and the blank of the method is filled.

The application relates to the technical field of medical dressing preparation, and discloses a hemostatic, healing-promoting and antibacterial foam dressing and a preparation method thereof. The method uses sodium alginate and carboxymethyl chitosan as a composite polysaccharide matrix, mixes the two, adds a calcium chloride solution to crosslink a porous gel support, and then carries out freeze-drying to obtain a porous framework; gelatin and polyvinyl alcohol can be further added to enhance the mechanical strength, zeolite particles loaded with silver ions are added to achieve antibacterial performance, epidermal growth factor release microspheres are added to promote healing, and the dressing can be further subjected to heparinization, plasma surface modification, thrombin addition, salt precipitation pore formation and sterilization treatment. The dressing prepared by the method has the functions of synergistic hemostasis, antibiosis and healing promotion, has good biocompatibility and suitable mechanical strength, and has a simple preparation process, and can be used for various wound care.

The invention provides special gel for medical surgical site ice compress and a preparation method thereof, and relates to the technical field of medical treatment. The preparation raw materials at least comprise: a main polymer: polyvinyl alcohol (PVA), bacterial nanocellulose (BNC), and poly N-isopropylacrylamide; the functional additives comprise double modified starch (OSA + phosphate), nano-silver (the particle size is 20-50 nm), a thrombin-fibrinogen compound and EGF / bFGF microspheres (PLGA); and the auxiliary components comprise glycerol, citric acid and purified water. According to the multifunctional ice compress gel, a structure which is loose outside and tight inside is formed through freeze drying, the cold compress uniformity and the air circulation performance are improved, the double modified starch and the cross-linking agent cooperate, the degradation period is prolonged to 72 h, the replacement frequency is reduced, the multifunctional ice compress gel has the functions of physical cooling, hemostasis repair, antisepsis and anti-inflammation, the cooperative requirement of postoperative cold compress and wound surface nursing is met, and the multifunctional ice compress gel is worthy of popularization and application. The device is suitable for postoperative incision cold compress, burn / acute stage cooling and hemostasis of wounds and auxiliary repair of chronic wounds.

The application relates to the technical field of medicines, and discloses application of gymnemon and a medicine thereof.According to the application, the gymnemon can be used for preparing medicines related to cardiovascular diseases, including medicines for improving heart failure, inhibiting myocardial hypertrophy, improving vascular endothelial function and reducing blood pressure, and further used for preparing medicines for reducing expressions of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 and / or increasing serum NO level; the gymnemon can also be used for preparing medicines for regulating abnormal lipid metabolism, including medicines for reducing triglyceride and total cholesterol level; the gymnemon can also be used for preparing medicines for relieving liver injury, including medicines for reducing glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase level; and the gymnemon can also be used for preparing medicines for improving systemic inflammation and / or platelet and thrombin dysfunction.

The present application relates to a method for preparing and expanding a TSCM cell in vitro. Specifically, the method comprises: 1) obtaining an isolated CD8+ T cell; 2) activating the CD8+ T cell; 3) mixing the activated CD8+ T cell, a fibrinogen solution and a thrombin solution, and culturing same under conditions suitable for cell growth, so as to obtain a TSCM cell culture; and 4) bringing the culture into contact with a dispase so as to obtain a TSCM cell. The present application also relates to a kit for preparing and expanding a TSCM cell in vitro, the use of fibrinogen and thrombin in the preparation of a kit for preparing and expanding a TSCM cell in vitro, and a TSCM cell obtained by means of the method or kit of the present application.

The invention belongs to the technical field of biomedical material engineering, and discloses a hydrogel scaffold used for 3D tumor sphere culture and drug screening, the scaffold is formed by four-arm polyethylene glycol maleimide, fibrinogen and thrombin through Michael addition crosslinking and biopolymerization synergistically, the elastic modulus of 10-1000 Pa can be adjusted by regulating and controlling the proportion of all the components, and the hydrogel scaffold can be used for 3D tumor sphere culture and drug screening. Gel forming is completed within 5 min at the room temperature. The scaffold has the biological activity of fibrous protein and the structural stability of polyethylene glycol, can efficiently support HCT116 cells to form high-activity tumor balls, accurately simulate the in-vivo tumor microenvironment and remarkably improve the accuracy and repeatability of drug screening, is easy and convenient to operate, is compatible with a standard pore plate high-throughput platform and is suitable for drug sensitivity detection of personalized treatment of tumors.

The utility model provides a thrombin determination kit fixing frame convenient to expand, which relates to the technical field of medical instruments and comprises a fixing base. A fixing frame is inserted into the top end face of the fixing base, a partition plate is slidably connected into the fixing frame, a control rod is rotatably connected to the middle of the top end face of the partition plate, walking gears are symmetrically and rotatably connected to the left and right sides of the upper and lower end faces of the partition plate, and a locking pin is slidably connected into the partition plate in the middle of the top of the control rod. According to the thrombin determination kit fixing frame convenient to expand, the fixing frames are rapidly spliced through the connecting combination blocks, the connecting combination grooves and the butterfly nuts at the top and the connecting lug blocks and the connecting lug grooves at the bottom, a user can conveniently and rapidly expand the scale of the fixing frame according to actual requirements, and it is ensured that the overall structure is stable; therefore, the problems that a fixing frame is fixed in structure, single in mounting position, difficult to adapt to quantity change, low in space utilization rate and difficult to flexibly adjust a partition plate are solved.

The application belongs to the technical field of biotechnology, and particularly relates to a kind of snake venom polypeptide and application thereof.The snake venom polypeptide is polypeptide DACU-1, polypeptide DACU-2 or polypeptide DACU-3.The application provides a kind of new snake venom polypeptide, including three polypeptides, and the three polypeptides all have anti-platelet aggregation activity, and have the activity of inhibiting platelet aggregation under the stimulation of ADP, arachidonic acid, collagen, thrombin and other various activators, and have the potential to be developed into anti-platelet drugs, functional foods and health products.

The invention relates to the technical field of in-vitro diagnosis, in particular to a lupus anticoagulant detection kit based on recombinant snake venom enzyme and application of the lupus anticoagulant detection kit. The probe comprises a recombinant snake venom thrombin-like enzyme, a phospholipid-quantum dot conjugate, calcium ions, sodium citrate, trehalose, polyethylene glycol, L-histidine, EDTA-2Na, a Tris-HCl buffer solution, a nanogold-carbon nanotube composite probe, a graphene oxide-chitosan composite material, a fluorescence enhancer and a stabilizer. The kit disclosed by the invention is high in detection sensitivity, strong in matrix interference resistance, excellent in recombinant snake venom enzyme stability and good in batch-to-batch consistency, the detection specificity can be accurately verified, and the problem that the performance of a traditional kit is poor is solved.

The invention discloses a 5 / 8 / 5 chitosan clostridium diterpenoid compound, a biosynthetic gene cluster and application of the biosynthetic gene cluster, and relates to the technical field of biological medicines. A 5 / 8 / 5 chitin type diterpenoid biosynthetic gene cluster Thm in trichoderma harzianum is identified through a genome mining system, chitin diterpenoid compounds with diversified structures are obtained by means of heterologous expression, the obtained compounds are subjected to anti-thrombotic activity comprehensive evaluation, and the result shows that the compounds 6 and 31 can obviously inhibit vascular thrombosis, the compound 6 has a remarkable inhibition effect on collagen-induced platelet aggregation, and the compound 31 has a better inhibition capability on thrombin-induced platelet activation. The compounds 6 and 31 show powerful antithrombotic effects in artery, vein and pulmonary artery thrombosis models, so that powerful technical support is provided for development of antithrombotic drugs.

The present invention relates to a polypeptide derived from natural tridegin by structural modification, which may serve as an inhibitor of plasma coagulation factor XIIIa, and to pharmaceutical compositions comprising such polypeptide. The present invention further refers to such polypeptide or pharmaceutical composition for use in a method for treating or preventing a thrombotic event in a patient. Moreover, the invention relates to an endoprosthesis or an enzyme-linked immunosorbent assay (ELISA) plate coated with a polypeptide of the present invention. Furthermore, the invention also encompasses a recombinant fusion protein comprising this polypeptide linked to a fibrinolytic enzyme such as streptokinase, nattokinase or tPAs via a flexible peptide linker containing a thrombin-cleavable site. This construct allows selective inhibition of FXIIIa within a thrombus, while enabling thrombin-triggered release of the fibrinolytic enzyme to induce localized fibrinolysis, thereby achieving targeted dual-action thrombolytic therapy.

The present invention belongs to the fields of polypeptide synthesis and biomedicine technology, and specifically relates to a polypeptide PM7 and its application in preventing and treating thrombosis. The present invention obtains an original polypeptide from the transcriptome of the salivary gland of the leech Philippine cattle leech, and truncates the original polypeptide to bind to the fibrinogen binding site of thrombin, thereby interfering with the activity of thrombin. Furthermore, {d-Phe}-PRP is added to the N-terminus of the truncated polypeptide, and {d-Phe}-PRP and the truncated polypeptide are connected with a connecting polypeptide to obtain the polypeptide PM7. The polypeptide PM7 of the present invention has the activity of inhibiting thrombin, has a shorter half-life in the body, and is highly safe, thereby achieving the effect of preventing and treating thrombosis.

The application belongs to the field of thrombin apparatus and equipment, and relates to a thrombin apparatus, which comprises a frame structure, a reaction cup assembly, a reagent assembly, a sample assembly, a suction head assembly, an incubation and detection assembly and a mechanical arm group. The components of the application are integrated and installed on the mounting plate of the frame structure, the reaction cup assembly adopts gear and rack driving to realize automatic transfer of the cup rack, the reagent assembly realizes accurate temperature control of two kinds of reagents through a heating belt and a refrigeration module respectively, and the sample assembly and the suction head assembly adopt a pull-out structure, which is convenient for loading and unloading consumables. The application is compact in structure, convenient in operation and accurate in detection, and can be widely applied to thrombin detection scenes of medical institutions and scientific research laboratories at all levels.

The invention belongs to the technical field of medical diagnosis, and particularly relates to a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscesses and interactive application. According to the invention, it is found that six indexes including serum uric acid (UA), thrombin time (TT), neutrophil absolute value (NEUT #), age (Age), fever (Fever) and erythrocyte sedimentation rate (ESR) are related to the type of the lumbar major muscle abscess, and a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscess and interactive application are invented. And a first visual and quantifiable column diagram (Nomogram) prediction model for differential diagnosis of lumbar major muscle abscess is provided for the field. The technical problem that an abstract mathematical prediction model is converted into a visual graphic diagnosis tool which is intuitive in form and convenient to operate is solved, so that the visual graphic diagnosis tool can be separated from dependence on specific computing equipment, and clinical medical staff can quickly and accurately apply the visual graphic diagnosis tool on a diagnosis and treatment site conveniently.

The invention discloses an application of a TBOA analogue in preparation of a kit for testing platelet stress self-regulating force, and the platelet stress self-regulating force is reflected by the aggregation degree of platelets after being intervened by the TBOA analogue. The application focuses on a new mechanism of platelet activation, that is, when platelets are stimulated by activators such as thrombin, normal reactions of activation and aggregation are driven and maintained by adjusting uptake of glutamic acid by EAATs. Due to the clear action mechanism, the application can provide indexes and methods with higher specificity in diagnosis, treatment and prognosis evaluation of thrombotic diseases, and the pertinence is extremely high. According to the application, the influence of the TBOA analogue on the platelet aggregation degree is utilized to test the stress self-regulating force of the platelet, and new clinical application of the TBOA analogue is developed.

This invention discloses a method for preparing filler particles for targeted adsorption of low-density lipoprotein (LDL) in patients with atherosclerosis. The steps include: 1) washing D101 macroporous resin with ultrapure water and physiological saline; 2) adding fibrin and PBS solution for soaking; adding thrombin factor II; adding zinc gluconate during the reaction; 3) repeating step 2) at least three times and drying the D101 macroporous resin; 4) adding physiological saline and D101 macroporous resin to lyophilized protein ApoB100 and mixing thoroughly; 5) lyophilizing the resin obtained in step 4) while controlling the humidity at 65±5% to obtain the finished product. This application utilizes this adhesion effect to target the adsorption of foam cells in atherosclerosis, adsorbing foam cells through hemoperfusion, removing redundant blood lipid components in the body, reducing macrophage infiltration of organs and blood vessels, and reducing pathological changes in organs and blood vessels.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

The present invention relates to an absorbable internal hemostasis kit and an absorbable internal hemostatic agent, the kit comprising: a first syringe containing a powder mixture including gelatin, thrombin, and calcium chloride; a second syringe containing a mixed solution including a thermo-responsive gel, purified water, polyvinylpyrrolidone, polyethylene glycol, sodium chloride, and a protein extract obtained through a multi-stage decellularization process; and a connector for connecting the first syringe and the second syringe so that the powder mixture and the mixed solution can be combined, wherein the absorbable internal hemostatic agent according to the present invention promotes and activates primary physiological hemostasis through thrombin and provides a secondary physical hemostatic effect by gelling in a temperature range close to body temperature, while also offering additionally wound-healing effects, so as to achieve faster and more effective internal hemostasis.

The invention discloses an osteochondral integrated sponge scaffold as well as a preparation method and application thereof, and belongs to the field of osteochondral repair materials. The preparation method comprises the following steps: (1) mixing a collagen dispersion liquid and a polyvinyl alcohol solution, then adding a phosphate buffer solution and beta-tricalcium phosphate, and then obtaining lower-layer hydrogel through a pouring method; (2) mixing the collagen dispersion liquid with a polyvinyl alcohol solution, then adding a phosphate buffer solution, and then obtaining upper-layer hydrogel through a pouring method; and (3) pouring the upper-layer hydrogel on the lower-layer hydrogel, constructing a sponge scaffold through a multi-time freeze-thawing method and a freeze-drying method, and finally soaking the sponge scaffold in thrombin to obtain the osteochondral integrated sponge scaffold. The scaffold can adsorb platelet-rich plasma, has certain adhesion capacity, can realize in-situ fixation and biological integration at a defect part, can well recover physical and biological dysfunctions of bone joints and osteochondral bones, and provides a potential application idea for clinical treatment of osteochondral defects.

The invention relates to the technical field of enzyme engineering and bioactive peptide preparation, and discloses a preparation method of horse myocardial peptide with antioxidant and antithrombotic effects, and the preparation method comprises the following steps: S1, pretreating horse heart tissue to obtain horse myocardial pulp; s2, composite enzymatic hydrolysis and guiding agent regulation and control: adding a composite enzyme system and an anti-thrombus guiding agent into the horse myocardial plasma; and S3, affinity chromatography enrichment. According to the method disclosed by the invention, a composite enzymolysis, guide regulation and control and affinity enrichment synergistic process is constructed, so that the technical problems of incomplete tissue crushing, low enzymolysis efficiency, insufficient bioactive peptide yield and easiness in oxidation and inactivation caused by high proportion of IIa type muscle fibers and compact connective tissues of horse myocardium are solved in a targeted manner, and a compound enzyme system with a specific ratio is adopted to adapt to the characteristics of the horse myocardium; the enzymolysis efficiency is greatly improved, a cationic guiding agent is introduced to directionally improve the generation proportion of antithrombotic peptide fragments, efficient enrichment of target peptides is achieved by combining thrombin affinity chromatography, and the antithrombotic function is remarkably enhanced while high antioxidant activity is guaranteed.

The invention discloses a medical hemostatic sponge material and a preparation method thereof, and relates to the field of hemostatic materials. According to the medical hemostatic sponge material, silk fibroin and sodium carboxymethyl starch are adopted as main matrixes, a small amount of quaternized chitosan is compounded, the problem of acidic degradation of a traditional chitosan system is solved, and meanwhile the hemostatic activity of polysaccharide is reserved; the mussel mucin provides super-strong biological adhesion, so that the problem that the material falls off at a dynamic bleeding part is solved; the RADA16 polypeptide is self-assembled to form a nanofiber network, an extracellular matrix structure is simulated, platelet anchoring and tissue repair are promoted, and meanwhile, foreign matter reaction is reduced; diatom biomineralized silicon DBS activates an endogenous blood coagulation pathway through a surface silanol group, DMSN-loaded thrombin accurately activates exogenous blood coagulation, calcium glycerophosphate provides calcium ions to strengthen a blood coagulation cascade reaction, and the three parts cooperate to realize blood coagulation activation.

The present invention provides a method for preventing, treating or alleviating bleeding caused by an anticoagulant using an anticoagulant reversal agent. The anticoagulant reversal agent has a structure as shown in formula I, can well inhibit bleeding complications caused by anticoagulants, for example, bleeding complications caused by anticoagulants such as a thrombin direct inhibitor, and has the characteristics of broad spectrum and high efficiency.

The application relates to the technical field of medical treatment, and particularly discloses a preparation method of a physical thrombus for an animal model of a cerebrovascular disease, which comprises the following steps: S1, collecting fresh whole blood of an animal in a sterile manner, and rapidly transferring the whole blood into a pre-cooled syringe assembly within 60 seconds after collection; and S2, driving a piston of the syringe, so that the whole blood repeatedly passes through at least two needle heads with different inner diameters in a preset pulse variable speed mode in a constant temperature environment (37+ / -0.5 DEG C), wherein the whole blood is first injected through a needle head with a larger hole diameter, and finally injected through a needle head with a smaller hole diameter; the application fundamentally avoids the use of exogenous thrombin and other biochemical reagents, eliminates the interference of the biochemical reagents on a natural thrombus formation process and a final component, and directly and in situ activates an endogenous blood coagulation system by controlling physical shearing force suffered by the blood when passing through needle heads with different specifications, so as to promote platelet aggregation and fibrin network formation.